Quidel Corporation
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $87.35
- Today's High:
- $89.4
- Open Price:
- $88.64
- 52W Low:
- $66.88
- 52W High:
- $120.61
- Prev. Close:
- $87.86
- Volume:
- 296635
Company Statistics
- Market Cap.:
- $5.94 billion
- Book Value:
- 74.316
- Revenue TTM:
- $3.27 billion
- Operating Margin TTM:
- 30.37%
- Gross Profit TTM:
- $1.94 billion
- Profit Margin:
- 16.8%
- Return on Assets TTM:
- 10.99%
- Return on Equity TTM:
- 15.99%
Company Profile
Quidel Corporation had its IPO on 1991-02-01 under the ticker symbol QDEL.
The company operates in the Healthcare sector and Medical Instruments & Supplies industry. Quidel Corporation has a staff strength of 7,000 employees.
Stock update
Shares of Quidel Corporation opened at $88.64 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $87.35 - $89.4, and closed at $88.08.
This is a +0.25% increase from the previous day's closing price.
A total volume of 296,635 shares were traded at the close of the day’s session.
In the last one week, shares of Quidel Corporation have increased by +2.45%.
Quidel Corporation's Key Ratios
Quidel Corporation has a market cap of $5.94 billion, indicating a price to book ratio of 1.1627 and a price to sales ratio of 1.8735.
In the last 12-months Quidel Corporation’s revenue was $3.27 billion with a gross profit of $1.94 billion and an EBITDA of $1.27 billion. The EBITDA ratio measures Quidel Corporation's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Quidel Corporation’s operating margin was 30.37% while its return on assets stood at 10.99% with a return of equity of 15.99%.
In Q4, Quidel Corporation’s quarterly earnings growth was a negative -93.3% while revenue growth was a positive 36%.
Quidel Corporation’s PE and PEG Ratio
- Forward PE
- 16.4745
- Trailing PE
- 9.3428
- PEG
- 7.19
Its diluted EPS in the last 12-months stands at $9.51 per share while it has a forward price to earnings multiple of 16.4745 and a PEG multiple of 7.19. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Quidel Corporation’s profitability.
Quidel Corporation stock is trading at a EV to sales ratio of 2.6961 and a EV to EBITDA ratio of 6.3115. Its price to sales ratio in the trailing 12-months stood at 1.8735.
Quidel Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $8.86 billion
- Total Liabilities
- $521.30 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $111.80 million
- Dividend Payout Ratio
- 0%
Quidel Corporation ended 2023 with $8.86 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $8.86 billion while shareholder equity stood at $4.93 billion.
Quidel Corporation ended 2023 with $0 in deferred long-term liabilities, $521.30 million in other current liabilities, 30000.00 in common stock, $2.20 billion in retained earnings and $2.48 billion in goodwill. Its cash balance stood at $292.90 million and cash and short-term investments were $345.00 million. The company’s total short-term debt was $186,400,000 while long-term debt stood at $2.43 billion.
Quidel Corporation’s total current assets stands at $1.32 billion while long-term investments were $21.00 million and short-term investments were $52.10 million. Its net receivables were $453.90 million compared to accounts payable of $283.30 million and inventory worth $524.10 million.
In 2023, Quidel Corporation's operating cash flow was $0 while its capital expenditure stood at $111.80 million.
Comparatively, Quidel Corporation paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $88.08
- 52-Week High
- $120.61
- 52-Week Low
- $66.88
- Analyst Target Price
- $124.67
Quidel Corporation stock is currently trading at $88.08 per share. It touched a 52-week high of $120.61 and a 52-week low of $120.61. Analysts tracking the stock have a 12-month average target price of $124.67.
Its 50-day moving average was $87.17 and 200-day moving average was $87.79 The short ratio stood at 4.82 indicating a short percent outstanding of 0%.
Around 776.9% of the company’s stock are held by insiders while 9639% are held by institutions.
Frequently Asked Questions About Quidel Corporation
Similar Industry Stocks (Medical Instruments & Supplies)
Most Active
Top Gainers
Top Losers
About
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies and solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.